Option Care Health, Inc.

Valuation Analysis

About the Company

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, an

Option Care Health, Inc. Stock at a Glance

Option Care Health, Inc. (OPCH) is currently trading at $20.76 with a market capitalization of $3.3B. The trailing P/E ratio stands at 16.22x, with a forward P/E of 10.13x. The 52-week range spans from $18.01 to $36.80; the current price is 43.6% below the yearly high. Year-over-year revenue growth stands at +1.3%. The net profit margin stands at 3.64%.

💰 Dividend

Option Care Health, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

12 analysts rate Option Care Health, Inc. (OPCH) on consensus: Buy. The average price target is $28.58, implying +37.68% from the current price. Analyst price targets range from $22.00 to $39.00.

Option Care Health, Inc.: The Investment Case in Detail

Option Care Health, Inc. (OPCH) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 37.68% upside from current levels — analyst sentiment is firmly constructive. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 1.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 3.64%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Short interest sits at 10.97% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The PEG ratio at 1.17 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 10.13x is meaningfully below the trailing 16.22x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 37.68% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (10.97%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Option Care Health, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.